Back to School: How biopharma can reboot drug development. Access exclusive analysis here
PANC fell $1.29 (62%) to $0.80 on Tuesday after data from a Phase IIb trial
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury